Literature DB >> 7474102

A leucine triplet repeat sequence (LXX)4 in p6gag is important for Vpr incorporation into human immunodeficiency virus type 1 particles.

Y L Lu1, R P Bennett, J W Wills, R Gorelick, L Ratner.   

Abstract

Incorporation of Vpr into human immunodeficiency virus type 1 (HIV-1) virions is mediated by the Gag protein, independently of other viral components. We have coexpressed Vpr and Gag constructs in a vaccinia virus expression system in order to map the region of Gag involved in Vpr packaging. Deletion of the carboxyl-terminal p6 region of Gag impaired the ability of Gag to package Vpr. To confirm the role of p6 in Vpr packaging, Rous sarcoma virus (RSV)-HIV chimeras containing HIV-1 p6 were constructed. Although RSV Gag does not package Vpr into virus particles, a chimera containing HIV-1 p6 is sufficient for Vpr incorporation. To map the region of p6 involved in Vpr packaging, a series of p6 point mutations and deletion mutations was analyzed. Mutations in the N-terminal p6 proline-rich domain, for which preliminary evidence shows a marked decrease in virion incorporated RNA, did not affect Vpr incorporation. Deletion of residues 1 to 31 of HIV-1 p6 did not affect Vpr packaging, but residues 35 to 47, including an (LXX)4 domain, were required for Vpr incorporation into virus particles.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7474102      PMCID: PMC189602     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  46 in total

1.  Dual regulation of silent and productive infection in monocytes by distinct human immunodeficiency virus type 1 determinants.

Authors:  P Westervelt; T Henkel; D B Trowbridge; J Orenstein; J Heuser; H E Gendelman; L Ratner
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

2.  Product review. New mammalian expression vectors.

Authors:  B Moss; O Elroy-Stein; T Mizukami; W A Alexander; T R Fuerst
Journal:  Nature       Date:  1990-11-01       Impact factor: 49.962

3.  Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release.

Authors:  H G Göttlinger; T Dorfman; J G Sodroski; W A Haseltine
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

4.  Functional domains of HIV-1 gag-polyprotein expressed in baculovirus-infected cells.

Authors:  M Royer; M Cerutti; B Gay; S S Hong; G Devauchelle; P Boulanger
Journal:  Virology       Date:  1991-09       Impact factor: 3.616

5.  Form, function, and use of retroviral gag proteins.

Authors:  J W Wills; R C Craven
Journal:  AIDS       Date:  1991-06       Impact factor: 4.177

6.  Incorporation of chimeric gag protein into retroviral particles.

Authors:  R A Weldon; C R Erdie; M G Oliver; J W Wills
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

7.  Human immunodeficiency virus vpr gene encodes a virion-associated protein.

Authors:  X Yuan; Z Matsuda; M Matsuda; M Essex; T H Lee
Journal:  AIDS Res Hum Retroviruses       Date:  1990-11       Impact factor: 2.205

8.  An infectious molecular clone of an unusual macrophage-tropic and highly cytopathic strain of human immunodeficiency virus type 1.

Authors:  R Collman; J W Balliet; S A Gregory; H Friedman; D L Kolson; N Nathanson; A Srinivasan
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

9.  Role of the gag and pol genes of human immunodeficiency virus in the morphogenesis and maturation of retrovirus-like particles expressed by recombinant vaccinia virus: an ultrastructural study.

Authors:  N Hoshikawa; A Kojima; A Yasuda; E Takayashiki; S Masuko; J Chiba; T Sata; T Kurata
Journal:  J Gen Virol       Date:  1991-10       Impact factor: 3.891

10.  Evolution of the primate lentiviruses: evidence from vpx and vpr.

Authors:  M Tristem; C Marshall; A Karpas; F Hill
Journal:  EMBO J       Date:  1992-09       Impact factor: 11.598

View more
  66 in total

1.  The C-terminal proline-rich tail of human immunodeficiency virus type 2 Vpx is necessary for nuclear localization of the viral preintegration complex in nondividing cells.

Authors:  H A Pancio; N Vander Heyden; L Ratner
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

2.  Nuclear export of human immunodeficiency virus type 1 Vpr is not required for virion packaging.

Authors:  Y Jenkins; P V Sanchez; B E Meyer; M H Malim
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

3.  Biochemical analyses of the interactions between human immunodeficiency virus type 1 Vpr and p6(Gag).

Authors:  Y Jenkins; O Pornillos; R L Rich; D G Myszka; W I Sundquist; M H Malim
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

4.  Human immunodeficiency virus type 1 Vpr contains two leucine-rich helices that mediate glucocorticoid receptor coactivation independently of its effects on G(2) cell cycle arrest.

Authors:  M P Sherman; C M de Noronha; D Pearce; W C Greene
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

5.  Integrase-lexA fusion proteins incorporated into human immunodeficiency virus type 1 that contains a catalytically inactive integrase gene are functional to mediate integration.

Authors:  M L Holmes-Son; S A Chow
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

6.  Human immunodeficiency virus type 1 vpr induces apoptosis through caspase activation.

Authors:  S A Stewart; B Poon; J Y Song; I S Chen
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

7.  Distinct nucleic acid interaction properties of HIV-1 nucleocapsid protein precursor NCp15 explain reduced viral infectivity.

Authors:  Wei Wang; Nada Naiyer; Mithun Mitra; Jialin Li; Mark C Williams; Ioulia Rouzina; Robert J Gorelick; Zhengrong Wu; Karin Musier-Forsyth
Journal:  Nucleic Acids Res       Date:  2014-05-09       Impact factor: 16.971

8.  HIV-1 Vpr up-regulates expression of ligands for the activating NKG2D receptor and promotes NK cell-mediated killing.

Authors:  Jonathan Richard; Sardar Sindhu; Tram N Q Pham; Jean-Philippe Belzile; Eric A Cohen
Journal:  Blood       Date:  2009-12-14       Impact factor: 22.113

9.  Virion-targeted viral inactivation of human immunodeficiency virus type 1 by using Vpr fusion proteins.

Authors:  G P Kobinger; A Borsetti; Z Nie; J Mercier; N Daniel; H G Göttlinger; A Cohen
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

10.  Human immunodeficiency virus type 1 Vpr binds to the N lobe of the Wee1 kinase domain and enhances kinase activity for CDC2.

Authors:  Masakazu Kamata; Nobumoto Watanabe; Yoshiko Nagaoka; Irvin S Y Chen
Journal:  J Virol       Date:  2008-04-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.